Jecho Biopharmaceuticals Co., Ltd.

9 clinical trials · Sponsor

Record	Firm	Date
JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NCT07603479)	Jecho Biopharmaceuticals Co., Ltd.	2026-06-25
A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM) (NCT07501559)	Jecho Biopharmaceuticals Co., Ltd.	2026-06-17
Recombinant Human Interleukin-7 (JL18008) for the Treatment of HIV-Infected Immunological Non-Responders (NCT07443228)	Jecho Biopharmaceuticals Co., Ltd.	2026-05-30
A Study to Evaluate JL18008 in Subject With HIV Immunological Non-Responders (NCT07579741)	Jecho Biopharmaceuticals Co., Ltd.	2026-05-26
A Phase I/II Study of JL19001 Injection Alone or in Combination With BCG in Subjects With High Risk Non-Muscle Invasive Bladder Cancer. (NCT07483970)	Jecho Biopharmaceuticals Co., Ltd.	2026-05-18
A Phase I Study of JLM019 Injection (NCT07623850)	Jecho Biopharmaceuticals Co., Ltd.	2026-01-13
To Evaluate the Safety of JL18008 (NCT07629310)	Jecho Biopharmaceuticals Co., Ltd.	2024-06-13
A Phase I Study to Evaluate the Safety and Tolerability of JL15003 Injection in Patients With Recurrent Glioblastoma (NCT07497373)	Jecho Biopharmaceuticals Co., Ltd.	2022-11-16
A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD) (NCT07389577)	Jecho Biopharmaceuticals Co., Ltd.	2022-03-01

Every clearance here is in the API, with alerts when new ones post.